Bill Snyder Archive — Page 4 of 119

C. difficile bacteria (image courtesy of CDC/Jennifer Oosthuizen)
February 18, 2026

Vanderbilt research offers new hope for preventing repeated C. diff infections

Treatment options are limited for the more than 500,000 people in the U.S. who are diagnosed annually with C. diff infections, but researchers are working on potential vaccines, therapeutic antibodies and — most recently — nanobodies, to prevent and treat C. diff infections.

(iStock)
February 13, 2026

Anti-Marburg antibody from Vanderbilt Health sent to Ethiopia during outbreak

There currently are no approved treatments or vaccines to protect against the infection, which can cause internal bleeding, organ failure, and in roughly 50% of cases, death.

February 11, 2026

Vaccination cuts risk of COVID-19 respiratory failure or death by 80%

Researchers at Vanderbilt Health and around the country continue to evaluate the effectiveness of vaccines approved by the Food and Drug Administration to reduce the severity and lethality of respiratory infections caused by the ever-mutating SARS-CoV-2 virus.

February 9, 2026

Vanderbilt research uncovers new clue to insulin resistance

The latest findings could lead to more targeted ways to increase insulin-stimulated glucose uptake by muscle and exercise tolerance.

February 4, 2026

Vanderbilt Health’s Vineet Agrawal, Fabian Bock among 2026 ASCI Young Physician-Scientist awardees

Since 2014, 27 Vanderbilt faculty members have received the annual award, which recognizes “notable achievements” by researchers early in their first faculty appointments.

Stokes Peebles, MD, right, Mark Rusznak, PhD, and their colleagues have identified a potential drug target for treating asthma. (photo by Erin O. Smith)
February 4, 2026

Broad genetic study reveals new drug target for asthma

The findings could bring relief to the more than 26 million people in the United States with asthma, a chronic and complex inflammatory disease of the airways.